Xuekui Liu
Zimberelimab(Xuekui Liu)은 Prostatic Neoplasms, Castration-Resistan 표적 항체로, Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable 영역에서 개발·상용화 중입니다. 작용기전: Targeting the adenosine pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 12.2% (ClinicalTrials.gov NCT04854499). 차별점: novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2α dependent transcription.
Prostatic Neoplasms, Castration-Resistan
Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
Recruiting
ADC and immunotherapy combinations are effective in advanced NS
govitecan and zimberelimab for 8 cycles followed
humanized anti-programmed cell death protein-1 (PD-1) antibody, administered intravenously every 2 weeks, was
novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2α dependent transcription
Targeting the adenosine pathway
T cell activation
apoptosis, influencing cell proliferation, and eventually leading to tumor cell death and inhibiting cancer progression
PD-L1) tumor expression
downregulation of NR4A expression was associated with T cell activation and improved OS, pointing to a biological link between tumor a
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Xuekui Liu
Zimberelimab(Xuekui Liu)은 Prostatic Neoplasms, Castration-Resistan 표적 항체로, Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable 영역에서 개발·상용화 중입니다. 작용기전: Targeting the adenosine pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 12.2% (ClinicalTrials.gov NCT04854499). 차별점: novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2α dependent transcription.
Prostatic Neoplasms, Castration-Resistan
Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
Recruiting
ADC and immunotherapy combinations are effective in advanced NS
govitecan and zimberelimab for 8 cycles followed
humanized anti-programmed cell death protein-1 (PD-1) antibody, administered intravenously every 2 weeks, was
novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2α dependent transcription
Targeting the adenosine pathway
T cell activation
apoptosis, influencing cell proliferation, and eventually leading to tumor cell death and inhibiting cancer progression
PD-L1) tumor expression
downregulation of NR4A expression was associated with T cell activation and improved OS, pointing to a biological link between tumor a
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.